Carregant...
Risk of infections associated with biological treatment in inflammatory bowel disease
Tumor necrosis factor-α (TNF-α) inhibitors are biological agents introduced in the late 1990s for the treatment of different immune-mediated diseases as inflammatory bowel disease, rheumatoid arthritis and psoriasis. The most commonly used TNF-α antagonists are infliximab, adalimumab, and certolizum...
Guardat en:
| Publicat a: | World J Gastroenterol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Baishideng Publishing Group Inc
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4239487/ https://ncbi.nlm.nih.gov/pubmed/25473153 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v20.i43.16014 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|